http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 23 Jun 2026 15:48:44 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/Natera+%28NTRA%29+PT+Raised+to+%24270+at+BTIG/26679271.html (Updated - June 23, 2026 3:48 PM EDT) <p>BTIG analyst Mark Massaro raised the price target on Natera (NASDAQ: NTRA) to $270.00 (from $250.00) while maintaining a Buy rating.</p><p>The analyst commented: "Shares of NTRA are up 3% today following news that NTRA's bread-and-butter Signatera MRD test is now included in important NCCN guidelines. The indication is for muscle-invasive bladder cancer (MIBC), and the timing comes ~1 month after NTRA obtained FDA approval of Signatera as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in MIBC. We believe Signatera's inclusion into NCCN guidelines is a major catalyst and represented http://www.streetinsider.com/Analyst+PT+Change/Natera+%28NTRA%29+PT+Raised+to+%24270+at+BTIG/26679271.html Tue, 23 Jun 2026 15:48:44 -0400 NTRA http://www.streetinsider.com/Analyst+Comments/Natera+%28NTRA%29+PT+Raised+to+%24270+at+BTIG/26679271.html (Updated - June 23, 2026 3:48 PM EDT) <p>BTIG analyst Mark Massaro raised the price target on Natera (NASDAQ: NTRA) to $270.00 (from $250.00) while maintaining a Buy rating.</p><p>The analyst commented: "Shares of NTRA are up 3% today following news that NTRA's bread-and-butter Signatera MRD test is now included in important NCCN guidelines. The indication is for muscle-invasive bladder cancer (MIBC), and the timing comes ~1 month after NTRA obtained FDA approval of Signatera as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in MIBC. We believe Signatera's inclusion into NCCN guidelines is a major catalyst and represented http://www.streetinsider.com/Analyst+Comments/Natera+%28NTRA%29+PT+Raised+to+%24270+at+BTIG/26679271.html Tue, 23 Jun 2026 15:48:44 -0400 NTRA http://www.streetinsider.com/Corporate+News/NCCN+adds+Natera%27s+Signatera+to+bladder+cancer+treatment+guidelines/26675180.html <p>Natera, Inc. (NASDAQ: NTRA) announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include ctDNA-based molecular residual disease (MRD) testing in the treatment algorithm for patients with muscle-invasive bladder cancer (MIBC).</p><p>The updated guidelines recommend consideration of ctDNA-MRD testing for risk stratification and to guide adjuvant immunotherapy decisions after cystectomy in patients who have not previously received immune checkpoint inhibitor treatment. The recommendation specifies use of an FDA-approved, personalized, tumor-informed, multiplex PCR-NGS assay for ctDNA.</p><p>Natera's Signatera test received a Category 1 recommendation — NCCN's highest designation — for guiding adjuvant http://www.streetinsider.com/Corporate+News/NCCN+adds+Natera%27s+Signatera+to+bladder+cancer+treatment+guidelines/26675180.html Tue, 23 Jun 2026 06:01:36 -0400 NTRA http://www.streetinsider.com/Press+Releases/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html <p class="bwalignc"><i>NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC)</i></p><p class="bwalignc"><i>Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54558680&amp;newsitemid=20260623843077&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=273&amp;md5=b86f540e9ea213b152416ba1cc640e44" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed multiplex PCR circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing in the treatment algorithm for patients with MIBC.</p><p>The http://www.streetinsider.com/Press+Releases/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html Tue, 23 Jun 2026 06:00:00 -0400 A.06822034 NTRA O.05077750 O.20026344 http://www.streetinsider.com/Press+Releases/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html <p class="bwalignc"><i>NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC)</i></p><p class="bwalignc"><i>Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54558680&amp;newsitemid=20260623843077&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=273&amp;md5=b86f540e9ea213b152416ba1cc640e44" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed multiplex PCR circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing in the treatment algorithm for patients with MIBC.</p><p>The http://www.streetinsider.com/Press+Releases/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html Tue, 23 Jun 2026 06:00:00 -0400 A.06822034 NTRA O.05077750 O.20026344 http://www.streetinsider.com/Press+Releases/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html <p class="bwalignc"><i>NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC)</i></p><p class="bwalignc"><i>Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54558680&amp;newsitemid=20260623843077&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=273&amp;md5=b86f540e9ea213b152416ba1cc640e44" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed multiplex PCR circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing in the treatment algorithm for patients with MIBC.</p><p>The http://www.streetinsider.com/Press+Releases/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html Tue, 23 Jun 2026 06:00:00 -0400 A.06822034 NTRA O.05077750 O.20026344 http://www.streetinsider.com/Press+Releases/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html <p class="bwalignc"><i>NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC)</i></p><p class="bwalignc"><i>Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54558680&amp;newsitemid=20260623843077&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=273&amp;md5=b86f540e9ea213b152416ba1cc640e44" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed multiplex PCR circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing in the treatment algorithm for patients with MIBC.</p><p>The http://www.streetinsider.com/Press+Releases/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html Tue, 23 Jun 2026 06:00:00 -0400 A.06822034 NTRA O.05077750 O.20026344 http://www.streetinsider.com/Business+Wire/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html <p class="bwalignc"><i>NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC)</i></p><p class="bwalignc"><i>Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54558680&amp;newsitemid=20260623843077&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=273&amp;md5=b86f540e9ea213b152416ba1cc640e44" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed multiplex PCR circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing in the treatment algorithm for patients with MIBC.</p><p>The http://www.streetinsider.com/Business+Wire/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html Tue, 23 Jun 2026 06:00:00 -0400 A.06822034 NTRA O.05077750 O.20026344 http://www.streetinsider.com/Business+Wire/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html <p class="bwalignc"><i>NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC)</i></p><p class="bwalignc"><i>Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54558680&amp;newsitemid=20260623843077&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=273&amp;md5=b86f540e9ea213b152416ba1cc640e44" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed multiplex PCR circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing in the treatment algorithm for patients with MIBC.</p><p>The http://www.streetinsider.com/Business+Wire/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html Tue, 23 Jun 2026 06:00:00 -0400 A.06822034 NTRA O.05077750 O.20026344 http://www.streetinsider.com/Business+Wire/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html <p class="bwalignc"><i>NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC)</i></p><p class="bwalignc"><i>Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54558680&amp;newsitemid=20260623843077&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=273&amp;md5=b86f540e9ea213b152416ba1cc640e44" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed multiplex PCR circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing in the treatment algorithm for patients with MIBC.</p><p>The http://www.streetinsider.com/Business+Wire/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html Tue, 23 Jun 2026 06:00:00 -0400 A.06822034 NTRA O.05077750 O.20026344 http://www.streetinsider.com/Business+Wire/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html <p class="bwalignc"><i>NCCN Category 1 recognition for Signatera-guided adjuvant treatment in muscle-invasive bladder cancer (MIBC)</i></p><p class="bwalignc"><i>Marks third NCCN guideline recommendation on ctDNA-MRD testing, following positive guideline changes in merkel cell carcinoma and diffuse large b-cell lymphoma</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54558680&amp;newsitemid=20260623843077&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=273&amp;md5=b86f540e9ea213b152416ba1cc640e44" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed multiplex PCR circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) testing in the treatment algorithm for patients with MIBC.</p><p>The http://www.streetinsider.com/Business+Wire/NCCN+Recommends+ctDNA-MRD+Testing+Using+Signatera%E2%84%A2+Technology+in+Landmark+Bladder+Cancer+Guideline+Update/26675141.html Tue, 23 Jun 2026 06:00:00 -0400 A.06822034 NTRA O.05077750 O.20026344 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+17++Filed+by%3A+Sheena+Jonathan/26674641.html si-local-file:///var/storage/secattach/20260622/26674641.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+17++Filed+by%3A+Sheena+Jonathan/26674641.html Mon, 22 Jun 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+17++Filed+by%3A+Sheena+Jonathan/26674641.html si-local-file:///var/storage/secattach/20260622/26674641.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+17++Filed+by%3A+Sheena+Jonathan/26674641.html Mon, 22 Jun 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/Corporate+News/Natera+to+present+21+studies+on+transplant+test+at+ATC/26662160.html <p>Natera, Inc. (NASDAQ: NTRA) announced it will present 21 studies, including seven oral presentations, at the American Transplant Congress (ATC), scheduled for June 20-24, 2026. The presentations focus on the company's Prospera donor-derived cell-free DNA (dd-cfDNA) test for kidney, heart, lung, and multi-organ transplant monitoring.</p><p>Two studies are among the highlighted data. The PEDAL study, involving 346 kidney transplant patients with non-rejection biopsy results, found that 18.2% had positive Prospera results. Those patients showed significantly higher rates of adverse outcomes, including more than six times the rate of graft loss compared to patients with negative results.</p><p>A separate analysis from the ProActive http://www.streetinsider.com/Corporate+News/Natera+to+present+21+studies+on+transplant+test+at+ATC/26662160.html Thu, 18 Jun 2026 06:01:24 -0400 NTRA http://www.streetinsider.com/FDA/Natera+to+present+21+studies+on+transplant+test+at+ATC/26662160.html <p>Natera, Inc. (NASDAQ: NTRA) announced it will present 21 studies, including seven oral presentations, at the American Transplant Congress (ATC), scheduled for June 20-24, 2026. The presentations focus on the company's Prospera donor-derived cell-free DNA (dd-cfDNA) test for kidney, heart, lung, and multi-organ transplant monitoring.</p><p>Two studies are among the highlighted data. The PEDAL study, involving 346 kidney transplant patients with non-rejection biopsy results, found that 18.2% had positive Prospera results. Those patients showed significantly higher rates of adverse outcomes, including more than six times the rate of graft loss compared to patients with negative results.</p><p>A separate analysis from the ProActive http://www.streetinsider.com/FDA/Natera+to+present+21+studies+on+transplant+test+at+ATC/26662160.html Thu, 18 Jun 2026 06:01:24 -0400 NTRA http://www.streetinsider.com/Press+Releases/Natera+to+Showcase+Organ+Health+Leadership+with+21+Presentations+at+the+American+Transplant+Congress/26662133.html <p class="bwalignc"><i>Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54556267&amp;newsitemid=20260618969671&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=89&amp;md5=78f0769935dd1625dc92c1f0505bb81f" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026. The company and its collaborators will share 21 presentations, including seven oral presentations, highlighting the utility of the Prospera test to inform risk assessment and long-term graft monitoring across kidney, heart, lung, and multi-organ transplant.</p><p>Some of the most anticipated Prospera study data to be http://www.streetinsider.com/Press+Releases/Natera+to+Showcase+Organ+Health+Leadership+with+21+Presentations+at+the+American+Transplant+Congress/26662133.html Thu, 18 Jun 2026 06:00:00 -0400 NTRA O.05077750 http://www.streetinsider.com/Press+Releases/Natera+to+Showcase+Organ+Health+Leadership+with+21+Presentations+at+the+American+Transplant+Congress/26662133.html <p class="bwalignc"><i>Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54556267&amp;newsitemid=20260618969671&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=89&amp;md5=78f0769935dd1625dc92c1f0505bb81f" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026. The company and its collaborators will share 21 presentations, including seven oral presentations, highlighting the utility of the Prospera test to inform risk assessment and long-term graft monitoring across kidney, heart, lung, and multi-organ transplant.</p><p>Some of the most anticipated Prospera study data to be http://www.streetinsider.com/Press+Releases/Natera+to+Showcase+Organ+Health+Leadership+with+21+Presentations+at+the+American+Transplant+Congress/26662133.html Thu, 18 Jun 2026 06:00:00 -0400 NTRA O.05077750 http://www.streetinsider.com/Business+Wire/Natera+to+Showcase+Organ+Health+Leadership+with+21+Presentations+at+the+American+Transplant+Congress/26662133.html <p class="bwalignc"><i>Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54556267&amp;newsitemid=20260618969671&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=89&amp;md5=78f0769935dd1625dc92c1f0505bb81f" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026. The company and its collaborators will share 21 presentations, including seven oral presentations, highlighting the utility of the Prospera test to inform risk assessment and long-term graft monitoring across kidney, heart, lung, and multi-organ transplant.</p><p>Some of the most anticipated Prospera study data to be http://www.streetinsider.com/Business+Wire/Natera+to+Showcase+Organ+Health+Leadership+with+21+Presentations+at+the+American+Transplant+Congress/26662133.html Thu, 18 Jun 2026 06:00:00 -0400 NTRA O.05077750 http://www.streetinsider.com/Business+Wire/Natera+to+Showcase+Organ+Health+Leadership+with+21+Presentations+at+the+American+Transplant+Congress/26662133.html <p class="bwalignc"><i>Data, including seven oral presentations, highlight the clinical utility of Prospera™ across multiple organs</i></p> <p> AUSTIN, Texas--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54556267&amp;newsitemid=20260618969671&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=89&amp;md5=78f0769935dd1625dc92c1f0505bb81f" shape="rect">Natera, Inc.</a> (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced its robust scientific presence at the upcoming American Transplant Congress (ATC), taking place June 20-24, 2026. The company and its collaborators will share 21 presentations, including seven oral presentations, highlighting the utility of the Prospera test to inform risk assessment and long-term graft monitoring across kidney, heart, lung, and multi-organ transplant.</p><p>Some of the most anticipated Prospera study data to be http://www.streetinsider.com/Business+Wire/Natera+to+Showcase+Organ+Health+Leadership+with+21+Presentations+at+the+American+Transplant+Congress/26662133.html Thu, 18 Jun 2026 06:00:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+15++Filed+by%3A+Sheena+Jonathan/26661606.html si-local-file:///var/storage/secattach/20260617/26661606.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+15++Filed+by%3A+Sheena+Jonathan/26661606.html Wed, 17 Jun 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+15++Filed+by%3A+Sheena+Jonathan/26661606.html si-local-file:///var/storage/secattach/20260617/26661606.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+15++Filed+by%3A+Sheena+Jonathan/26661606.html Wed, 17 Jun 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+16++Filed+by%3A+Chapman+Rowan+E/26661607.html si-local-file:///var/storage/secattach/20260617/26661607.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+16++Filed+by%3A+Chapman+Rowan+E/26661607.html Wed, 17 Jun 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+16++Filed+by%3A+Chapman+Rowan+E/26661607.html si-local-file:///var/storage/secattach/20260617/26661607.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+16++Filed+by%3A+Chapman+Rowan+E/26661607.html Wed, 17 Jun 2026 21:05:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+12++Filed+by%3A+Rabinowitz+Matthew/26655810.html si-local-file:///var/storage/secattach/20260616/26655810.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+12++Filed+by%3A+Rabinowitz+Matthew/26655810.html Tue, 16 Jun 2026 21:35:00 -0400 NTRA O.05077750 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+12++Filed+by%3A+Rabinowitz+Matthew/26655810.html si-local-file:///var/storage/secattach/20260616/26655810.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Natera%2C+Inc.++++++++++++++For%3A+Jun+12++Filed+by%3A+Rabinowitz+Matthew/26655810.html Tue, 16 Jun 2026 21:35:00 -0400 NTRA O.05077750